We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+13.87%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$257M
AUM Growth
+$29.3M
Cap. Flow
+$13.8M
Cap. Flow %
5.38%
Top 10 Hldgs %
63.16%
Holding
47
New
14
Increased
6
Reduced
6
Closed
13

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$15.1M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$11.8M
3
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$9.74M
4
RLYP
RELYPSA INC COM
RLYP
+$8.25M
5
ATRS
Antares Pharma, Inc.
ATRS
+$6.79M

Top Sells

Rank Stock Value
1
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$22.9M
2
CNXR
Connecture, Inc.
CNXR
+$15.2M
3
OFIX icon
Orthofix Medical
OFIX
+$10.8M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$7.07M
5
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$7M

Sector Composition

Rank Sector Weight
1 Healthcare 60.2%
2 Technology 16.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNXR
1
DELISTED
Connecture, Inc.
CNXR
$43.6M 16.99%
4,127,232
-1,375,733
-25% -$15.2M
ADMS
2
DELISTED
Adamas Pharmaceuticals
ADMS
$20.3M 7.9%
772,600
+163,950
+27% +$3.19M
VNDA icon
3
Vanda Pharmaceuticals
VNDA
$307M
$17.9M 6.99%
1,413,599
+25,000
+2% +$270K
FPRX
4
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$16.9M 6.57%
+678,595
New +$15.1M
SGYP
5
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$16.7M 6.5%
+2,009,984
New +$9.74M
DYAX
6
DELISTED
DYAX CORPORATION
DYAX
$12.5M 4.88%
472,739
+236,789
+100% +$6.28M
PRTK
7
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.7M 4.17%
+415,338
New +$11.8M
RLYP
8
DELISTED
RELYPSA INC COM
RLYP
$7.94M 3.1%
+240,000
New +$8.25M
ARCT icon
9
Arcturus Therapeutics
ARCT
$164M
$7.78M 3.03%
169,869
+29,328
+21% +$1.34M
ALIM
10
DELISTED
Alimera Sciences
ALIM
$7.76M 3.02%
112,211
-3,226
-3% -$223K
VIRX
11
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.65M 2.98%
12,102
+7,156
+145% +$3.8M
APYX icon
12
Apyx Medical
APYX
$173M
$7.48M 2.91%
2,680,000
+2,200,000
+458% +$6.05M
OCRX
13
DELISTED
Ocera Therapeutics, Inc.
OCRX
$7.46M 2.91%
1,963,777
– –
VCEL icon
14
Vericel Corp
VCEL
$2.35B
$7.45M 2.9%
2,086,028
– –
ARDM
15
DELISTED
Aradigm Corp Common Stock
ARDM
$7.4M 2.89%
1,002,962
– –
ATRS
16
DELISTED
Antares Pharma, Inc.
ATRS
$5.82M 2.27%
+2,800,000
New +$6.79M
AUPH icon
17
Aurinia Pharmaceuticals
AUPH
$1.91B
$5.81M 2.27%
1,941,144
– –
STML
18
DELISTED
Stemline Therapeutics, Inc.
STML
$5.59M 2.18%
475,200
– –
ASND icon
19
Ascendis Pharma A/S
ASND
$16B
$5.5M 2.14%
311,222
-28,641
-8% -$501K
LSTA icon
20
Lisata Therapeutics
LSTA
$9.02M
$4.63M 1.8%
+16,507
New +$6.13M
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
$4.2M 1.64%
+312,500
New +$3.83M
ALBO
22
DELISTED
Albireo Pharma Inc
ALBO
$4.13M 1.61%
+133,717
New +$4.49M
TENX icon
23
Tenax Therapeutics
TENX
$363M
$4.09M 1.59%
35
– –
SGNT
24
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$3.45M 1.34%
+141,900
New +$3.4M
XNPT
25
DELISTED
XENOPORT, INC.
XNPT
$2.97M 1.16%
+485,000
New +$3.17M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2015 Portfolio in Review

As of Q2 2015, Great Point Partners held 47 positions worth $257M, up 13% from $227M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Great Point Partners deployed $13.8M of net new capital in Q2 2015, opening 14 new positions and adding to 6 existing holdings. Its largest new stake was Five Prime Therapeutics, Inc.: 678,595 shares worth $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 49% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Connecture, Inc., an estimated $15.2M trimmed.

  • Great Point Partners's largest Q2 2015 buy was Five Prime Therapeutics, Inc.: 678,595 shares worth $16.9M.
  • Great Point Partners added most to DYAX CORPORATION in Q2 2015, an estimated $6.28M increase.
  • Great Point Partners's biggest Q2 2015 reduction was Connecture, Inc., cutting an estimated $15.2M.
  • Great Point Partners fully exited HYPERION THERAPEUTICS INC COM STK (DE) in Q2 2015, selling an estimated $22.9M.
  • Great Point Partners's ten largest holdings make up 63% of its $257M portfolio in Q2 2015.
  • Great Point Partners opened 14 new positions and closed 13 in Q2 2015.
  • Great Point Partners's portfolio value rose 13% quarter-over-quarter to $257M.

Based on Great Point Partners's 13F filing for Q2 2015, filed 14 Aug 2015.